Digital Phablet

Tag: clinical trial

Major Study Shows Drug Safeguards Kidneys in Non-Diabetics

Chronic kidney disease (CKD) is a persistent condition where the kidneys gradually lose their ability to function properly. Early on, many individuals experience few symptoms, but over time, the disease can lead to kidney failure and elevate the risk of heart problems. One of the primary goals in nephrology is developing treatments that slow down this progression.

A recent international study offers promising news. Researchers discovered that finerenone, a medication already prescribed for some patients with diabetic kidney disease, can also offer benefits to those with CKD who do not have diabetes. These findings were published in the New England Journal of Medicine.

The study, known as FIND-CKD, was led by Professor Hiddo Lambers Heerspink from the University Medical Center Groningen. It involved 1,584 adults from various countries who all had decreased kidney function and excess protein in their urine. The presence of protein in the urine is an early warning sign of kidney damage and often indicates a higher likelihood of disease progression. Therefore, reducing protein levels in the urine is a crucial treatment target.

Participants were assigned either finerenone or a placebo while continuing their existing kidney-protective therapies. The researchers tracked them for just over three years to compare changes in kidney health. Kidney function was assessed using estimated glomerular filtration rate (eGFR). Those taking finerenone experienced a slower decline in eGFR, meaning their kidneys maintained better function longer than those on the placebo.

In addition, the drug lowered the risk of severe kidney and cardiovascular complications. About 13.9% of patients on finerenone faced major kidney events, heart failure hospitalizations, or cardiovascular death, compared to 16.9% in the placebo group. An Especially notable benefit was the significant reduction in protein levels in the urine — finerenone decreased urinary protein by over 41% on average, whereas the placebo group saw only a roughly 9% reduction. More than half of the patients receiving finerenone achieved reductions of at least 30%, which is associated with a more favorable outlook for kidney health.

Previously, most large studies on finerenone focused on individuals with type 2 diabetes. This research indicates that the medicine may be effective for a broader population because more than half of all people with CKD do not have diabetes.

Importantly, the study reported no unexpected safety issues during treatment. However, patients should only take finerenone under medical supervision, as kidney function and blood potassium levels require careful monitoring.

Overall, this high-quality clinical trial provides compelling evidence that finerenone could become a valuable addition to the standard treatment options for non-diabetic CKD. Future guidelines and real-world experiences will help clarify which patient groups will benefit the most.

If you’re interested in diabetes prevention, consider reading about five vitamins that may help prevent complications, along with tips on managing high blood pressure and diabetes through healthy eating. For additional health insights, explore recent studies on vitamin D and type 2 diabetes, and learn which fruits might be better suited for individuals with the condition.

July 23, 2026
Innovative Therapy Could Overcome Drug Resistance in Advanced Kidney Cancer

Credit: Unsplash+

One of the biggest hurdles in cancer treatment is the development of resistance to drugs. While initial therapies can effectively reduce tumors and slow disease progression, cancer cells often adapt over time, finding ways to survive despite ongoing treatment.

This issue is especially prevalent in advanced kidney cancer, where many patients eventually run out of effective treatment options.

Researchers at Mayo Clinic have shared promising early results from a clinical trial that may help overcome this challenge. Their study explored a new experimental drug called darlifarnib, used in combination with cabozantinib, a standard therapy for advanced clear cell renal cell carcinoma, the most common type of kidney cancer in adults.

Clear cell renal cell carcinoma accounts for the majority of kidney cancer cases. Although targeted therapies and immunotherapies have improved survival rates for many patients, the disease tends to become harder to control as resistance develops. This has driven researchers to look for treatments that can counteract the cancer’s ability to adapt.

The recent study aimed to determine if darlifarnib could boost the effects of cabozantinib. Scientists believe that darlifarnib may block critical signaling pathways that cancer cells use to grow and survive. By combining it with cabozantinib, the goal was to prevent tumors from exploiting alternative routes for growth.

This was a phase 1a/b trial, representing one of the initial tests of this drug combo in humans. Eighteen patients with advanced clear cell renal cell carcinoma participated. All had previously been treated with cabozantinib, with many having received multiple other therapies, including roughly half who had undergone three or more prior treatments.

This group faces significant unmet medical needs since treatment options tend to dwindle after several therapies fail. Discovering a treatment that remains effective in such cases would represent a substantial advancement.

Of the 16 patients evaluated, seven experienced measurable tumor reduction, resulting in a response rate of about 44%. Additionally, 94% of the assessable patients achieved disease control, meaning their tumors either shrank or remained stable.

Dr. Yousef Zakharia, the study’s lead researcher and a medical oncologist at Mayo Clinic in Arizona, described these preliminary results as encouraging. He emphasized the ongoing need for more effective treatments for advanced kidney cancer, sharing the findings at the 2026 International Kidney Cancer Symposium: Europe in Paris.

Researchers believe the combination’s effectiveness may stem from its ability to target multiple pathways that drive cancer growth. Cancer cells often survive treatments by activating backup mechanisms when one pathway is blocked. Adding darlifarnib could make it more difficult for tumors to employ these escape routes.

The significance of these early results is heightened by the fact that the patients involved had already shown disease progression despite previous treatments. The observed tumor shrinkage and disease stabilization suggest the combination might overcome some forms of resistance.

Nevertheless, experts caution interpreting early-stage data, as small studies can sometimes produce results that aren’t replicable in larger trials. The next step is to see if these benefits can be consistently achieved across a broader patient population.

Ongoing international trials will continue to evaluate this drug combo in additional patients. Future research will clarify how long responses last, whether survival improves, and which patients are most likely to benefit.

If the current positive trends persist, the combination of darlifarnib and cabozantinib could become a new treatment option for advanced kidney cancer patients who have exhausted standard therapies. Even small steps forward can have a meaningful impact for patients and their families facing this disease.

If you’re interested in cancer research, consider reading about how a low-carb diet might increase overall cancer risk and new strategies to extend the lifespan of cancer survivors.

For more health insights, explore recent studies on anti-cancer superfoods and findings indicating that daily vitamin D3 supplementation could reduce the risk of cancer death.

Source: Mayo Clinic.

June 10, 2026
Psychedelic Compound May Aid Persistent Depression Recovery

Depression remains one of the most widespread mental health issues globally, impacting individuals’ emotions, thoughts, and daily functioning. Although many find relief through antidepressants, therapy, or a combination of both, some continue to struggle despite trying various treatments. This persistent form of depression, known as treatment-resistant depression, is often among the most challenging to address.

For those afflicted, symptoms tend to linger for years. They may experience ongoing sadness, loss of interest in activities they once enjoyed, fatigue, sleep disturbances, trouble concentrating, and feelings of despair.

Because traditional treatments don’t work for everyone, researchers are actively exploring new options. One emerging treatment gaining attention is psilocybin—a naturally occurring psychedelic compound found in certain types of mushrooms.

Over the past decade, multiple carefully designed clinical studies have indicated that psilocybin can help alleviate depressive symptoms, even in cases unresponsive to standard treatments. Though these findings are promising, much remains unknown about how psilocybin performs outside of clinical trials, in everyday healthcare settings. Clinical research often involves tightly controlled environments and selective participants, which can differ markedly from real-world practice.

To better understand its practical effects, researchers in Switzerland reviewed medical records from patients who received psilocybin at the Psychiatric University Hospital Zurich. Their objective was to see whether the positive outcomes observed in research could also be achieved through routine clinical care.

The study involved 19 patients with varying degrees of treatment-resistant depression—from mild to severe. Each patient underwent between one and four supervised psilocybin sessions as part of their treatment plan. The team then evaluated changes in depression symptoms before and after the therapy.

Results showed substantial improvement. Using clinician-rated depression scales, scores dropped significantly post-treatment. On average, patients’ scores decreased from about 31 out of 60 before treatment to around 20 out of 60 within six weeks after their last session. Patients also rated their own feelings of depression, which declined from an average of 32 out of 63 to 23 out of 63 after treatment. These changes suggest both healthcare providers and patients perceived meaningful symptom relief.

Side effects were monitored throughout. They occurred in 30 of the 40 treatment sessions, but most were mild and temporary—common issues included fatigue, headaches, and tearfulness. Crucially, no serious or long-lasting adverse effects were observed.

Scientists believe psilocybin functions differently from traditional antidepressants. It’s thought to temporarily enhance communication between different brain regions, helping individuals break free from rigid thought patterns and emotional loops. This increased neural flexibility might foster new perspectives on their experiences and feelings—potentially aiding recovery.

Interest in psychedelic-assisted therapies has surged in recent years, with studies focusing on depression, anxiety related to serious illness, addiction, and other mental health issues. While early results are optimistic, experts strongly recommend these treatments only be administered in carefully supervised medical settings.

This Swiss study provides valuable real-world evidence, suggesting that benefits seen in controlled research could translate into everyday healthcare environments. Nevertheless, the authors emphasize several limitations: the small sample size of only 19 patients, the absence of a control or placebo group, and the short follow-up period, leaving questions about the longevity of the improvements.

If you’re concerned about depression, consider exploring research on how dietary factors—like dairy products—might influence depression risk, or how B vitamins could play a preventive role against depression and anxiety. For broader mental health insights, recent studies also point to the potential impact of ultra-processed foods on mood and how extra-virgin olive oil might help reduce depressive symptoms.

This research was published in The Lancet Regional Health—Europe, based on findings from the Psychiatric University Hospital Zurich.

June 3, 2026
New mRNA Vaccine May Reduce Skin Cancer Mortality

Scientists have reported promising long-term results from a study combining a personalized mRNA vaccine with a leading immunotherapy drug to help prevent melanoma from returning.

The research, conducted by investigators at NYU Langone Health and its Perlmutter Cancer Center, indicates that this treatment approach could significantly improve survival rates and lower the risk of cancer metastasis. The findings were shared at the 2026 American Society of Clinical Oncology meeting and published in the Journal of Clinical Oncology.

Cancer therapies have seen dramatic changes over recent years. Once, options were primarily limited to surgery, chemotherapy, and radiation. Today, immunotherapy has become a cornerstone treatment, leveraging the body’s own immune system to fight cancer more effectively.

While immunotherapy has revolutionized care for many melanoma patients, its effectiveness varies. Some tumors develop ways to evade immune detection and may return months or even years after initial treatment.

To address this challenge, researchers developed a personalized vaccine called intismeran. Unlike traditional vaccines designed to prevent certain infections, this vaccine is tailored for each patient.

Researchers analyze a patient’s tumor tissue after surgery to identify dozens of abnormal proteins known as neoantigens. These neoantigens act like unique fingerprints that differentiate cancer cells from healthy ones.

Using mRNA technology, scientists then create a custom vaccine that contains instructions targeting these specific tumor markers. When injected, the vaccine trains the immune system to recognize and attack cells displaying these markers. The objective is to bolster immune cells to eliminate any remaining melanoma cells before they can form new tumors.

This vaccine was tested alongside pembrolizumab, a widely used immunotherapy drug that works by blocking a protein called PD-1 — a protein cancer cells often exploit to hide from immune detection. By inhibiting PD-1, pembrolizumab helps restore the immune system’s ability to identify and attack cancer.

From 2019 to 2021, the clinical trial enrolled patients in the U.S. and Australia. All had previously undergone surgery to remove melanoma. Researchers compared the outcomes of patients who received both the personalized vaccine and pembrolizumab with those who received only pembrolizumab.

After five years, the results showed a clear advantage for the combination group. Nearly 70% remained cancer-free, while less than 50% of those treated with just pembrolizumab achieved the same. The combined approach cut the risk of recurrence or death by nearly half.

Additionally, patients receiving the combined therapy were less likely to experience the spread of melanoma to distant organs—an essential factor since metastatic melanoma is much harder to treat and accounts for many cancer-related deaths. Survival rates were also notably higher among recipients of the personalized vaccine.

These findings provide some of the strongest evidence to date that mRNA technology can be effectively used against cancer.

While mRNA gained widespread attention during the pandemic, its potential in oncology has been under investigation for years. One major advantage of mRNA is its adaptability—scientists can quickly design treatments tailored to the genetic makeup of an individual’s tumor.

This personalized approach is especially promising for cancers like melanoma, which often harbor numerous mutations. The more unique markers a tumor has, the more targets the immune system can be trained to recognize and attack.

The safety profile observed in the study was encouraging, with most side effects being manageable, including fatigue, chills, and injection site discomfort. No serious safety issues emerged during the trial.

Despite these positive results, experts emphasize that further research is necessary. Since this was a Phase IIb trial, larger studies are needed before the treatment can become a standard option. Fortunately, a Phase III international trial is already in progress, which will help confirm the vaccine’s effectiveness on a broader scale.

Scientifically, these results are highly significant. They suggest that personalized vaccines could enhance existing immunotherapy treatments rather than replace them. This combined strategy might serve as a model for future cancer therapies.

However, given the small size of this study, cautious interpretation is advised until larger trials are completed. If future research confirms these findings, personalized mRNA vaccines could represent a major breakthrough in cancer treatment—potentially applicable to many different types of cancer.

For those interested in skin health, studies have linked fish consumption with a higher risk of skin cancer, while Vitamin B3 may help prevent skin cancers. Additional research discusses how vegetable oils might contribute to cancer spread and how vitamin D could assist in treating skin inflammation.

Source: NYU Langone Health

June 3, 2026
New Drug Offers Hope for Longer Pancreatic Cancer Survival

Credit: Unsplash+

Pancreatic cancer is notoriously difficult to treat and has one of the lowest survival rates among all cancers. Many patients are diagnosed at advanced stages when the disease has already spread, making effective treatment challenging. For years, medical professionals have been searching for better options to help extend patient lives.

Recent research from Northwestern Medicine, published in *Nature Medicine*, offers some promising developments. Scientists tested a new drug called elraglusib to determine if it could enhance survival rates when combined with standard chemotherapy.

The study involved over 200 patients with advanced pancreatic cancer, who were randomly assigned to two groups. One group received the typical chemotherapy treatment, while the other received chemotherapy plus the experimental drug.

The findings were encouraging. Patients treated with elraglusib lived longer than those who only received chemotherapy, with survival times extending by several months on average. For many, this additional time can be invaluable, allowing for more moments with loved ones.

Additionally, the likelihood of surviving at least one year was significantly higher in the group receiving the new drug. Nearly half of these patients were still alive after a year, compared to about 20% in the standard treatment group. Some even reached two years of survival, which is uncommon for this cancer type.

This drug is unique because it doesn’t attack cancer cells directly. Instead, it targets a protein in the body that promotes tumor growth and helps cancer evade the immune system. Blocking this protein could help the immune system better recognize and fight the tumor.

Further analysis suggested that elraglusib might boost the number of immune cells within tumors, indicating it may help “activate” the immune system’s natural defenses against cancer.

Like many cancer therapies, elraglusib can cause side effects such as fatigue and alterations in blood cell counts. However, medical teams reported these side effects were generally manageable.

While these results are promising, experts emphasize this is just an initial step. Larger, more comprehensive studies are necessary to confirm the findings and ensure the drug’s safety for broader use. Researchers are also exploring potential combinations of this drug with other emerging treatments.

Overall, this study demonstrates that innovative approaches in cancer therapy can make a meaningful difference, even with formidable diseases like pancreatic cancer. Though not a cure, it offers hope for improved outcomes and underscores the importance of ongoing research to build on these strides.

If you’re interested in cancer-related topics, consider looking into studies suggesting that a low-carb diet could increase overall cancer risk or explore berries’ role in preventing cancer, diabetes, and obesity.

For additional health insights, check out recent research on how drinking milk influences heart disease and cancer risks, along with findings indicating that vitamin D supplements might significantly lower cancer mortality.

Source: Northwestern University.

April 20, 2026